Clinical trial
Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909…
NCT00414336 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00414336 |
|---|---|
| Title | Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria |
| Official title | Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | National Institute of Allergy and Infectious Diseases@@@Coley Pharmaceutical Group |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Drug |
| Interventions | AMA1-C1/Alhydrogel + CPG 7909 Vaccine |
| Enrollment | 150 |
| Start date | Dec 15, 2006 |
| Primary completion | Dec 15, 2006 |
| Completion | Dec 15, 2006 |
| First posted | Dec 21, 2006 |
| Last update posted | Jul 2, 2017 |
| Countries | Mali |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: